Clinical Trial

A Prospective Study of Firmonertinib as First-line Adaptive Therapy Guided by Dynamic ctDNA (MRD) Changes in Locally Advanced or Metastatic EGFR-mutated Non-small Cell Lung Cancer

Name: A Prospective Study of Firmonertinib as First-line Adaptive Therapy Guided by Dynamic ctDNA (MRD) Changes in Locally Advanced or Metastatic EGFR-mutated Non-small Cell Lung Cancer — clinical trial record (NCT07661173)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

Exploring the efficacy and safety of adaptively adjusting treatment regimens based on ctDNA (MRD) status for EGFR mutation-positive NSCLC

Trial Details

NCT Number	NCT07661173
Lead Sponsor	Anhui Provincial Cancer Hospital
Conditions	Non Small Cell Lung Cancer
Enrollment	154 participants
Start Date	2026-06-06
Primary Completion	2029-03-06 (estimated)
Study Completion	2031-05-06 (estimated)
Updated on ClinicalTrials.gov	2026-06-22